Aims: Malignant rhabdoid tumours (MRTs) are highly aggressive malignancies of early infancy characterized by inactivation of SMARCB1, a core member of the SWI/SNF chromatin-remodelling complex. The aim of this study was to explore the status of multiple key subunits of the SWI/SNF complex in MRTs.

Methods And Results: We screened the key subunits of the SWI/SNF complex, including SMARCB1, SMARCA2, PBRM1, SMARCA4, and ARID1A, in four MRTs by immunohistochemistry, sequencing, and fluorescence in-situ hybridization (FISH). Complete loss of SMARCB1, SMARCA2 and PBRM1 expression and corresponding mutations in the same genes were observed in all cases. The mutations included seven missense, three same-sense, four frameshift and two truncating mutations. FISH revealed heterozygous deletion of SMARCB1 in one case, and monoploidy of chromosome 22, which harbours SMARCB1, in another case. Furthermore, trisomy of chromosome 9, which harbours SMARCA2, was observed in two cases. Abnormality of PBRM1 was not found in any case.

Conclusions: We report, for the first time, co-inactivation and frequent mutations of SMARCB1, SMARCA2 and PBRM1 in MRTs. Multiple subunit abnormalities of the SWI/SNF complex potentially act together to contribute to the tumorigenesis of MRTs, which provides unique insights into this disease.

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12632DOI Listing

Publication Analysis

Top Keywords

smarcb1 smarca2
16
smarca2 pbrm1
16
swi/snf complex
12
malignant rhabdoid
8
rhabdoid tumours
8
key subunits
8
subunits swi/snf
8
observed cases
8
smarcb1 case
8
chromosome harbours
8

Similar Publications

Article Synopsis
  • This study examined 16 cases of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), focusing on clinical features, molecular traits, and family genetics over a decade at Fudan University.
  • Patients had a mean diagnosis age of 28.7 years, with unique tumor characteristics; most were unilateral, with significant sizes, and misdiagnosed in many cases, while specific protein expressions were analyzed.
  • Survival rates over time were low, with only 22.6% surviving two years, highlighting the need for accurate diagnosis and better understanding of the disease's genetic components.
View Article and Find Full Text PDF

Unlabelled: Sinonasal carcinomas are aggressive neoplasms that present a high morbidity and mortality rate with an unfavorable prognosis. This group of tumors exhibits morphological and genetic diversity. Genetic and epigenetic alterations in these neoplasms are the current targets for diagnosis and treatment.

View Article and Find Full Text PDF

About 20% of human cancers harbor mutations of genes encoding switch/sucrose nonfermentable (SWI/SNF) complex subunits. Deficiency of subunits of the complex is present in 10% of non-small-cell lung cancers (NSCLC; SMARCA4/SMARCA2 deficient), 100% thoracic SMARCA4/A2-deficient undifferentiated tumors (TSADUDT; SMARCA4/A2 deficient), malignant rhabdoid tumor, and atypical/teratoid tumor (SMARCB1-deficient), >90% of small cell carcinoma of the ovary, hypercalcemic type (SMARCA4/SMARCA2 deficient), frequently in undifferentiated/dedifferentiated endometrial carcinoma (SMARCA4, SMARCA2, SMARCB1, and ARID1A/B deficient), 100% SMARCA4 deficient undifferentiated uterine sarcoma (SMARCA4 deficient); and in various other tumors from multifarious anatomical sites. Silencing of SWI/SNF gene expression may be genomically or epigenetically driven, causing loss of tumor suppression function or facilitating other oncogenic events.

View Article and Find Full Text PDF
Article Synopsis
  • The SWI/SNF complex is important in cancer biology, particularly as a marker for aggressive tumors, and understanding its expression can help tailor targeted therapies for patients with SWI/SNF-deficient pulmonary tumors.
  • This study focused on 101 patients with SWI/SNF-deficient pulmonary neoplasms, primarily examining the impact of immunotherapy and radiotherapy on survival rates, collecting data from a cancer center in Shanghai.
  • Results indicated that immunotherapy and radiotherapy significantly improved overall survival, with immunotherapy boosting 3-year survival rates dramatically and showing specific variations in effectiveness based on genetic mutations.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!